AstraZeneca: Very encouraging preliminary phase II data for AZD9291 in lung cancer

NEUTRAL, Fair Value  4830p (+19%)
News published on August Monday 24, 2015
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities